Complementary prediction of cardiovascular events by estimated apo-and lipoprotein concentrations in the working age population. The Health 2000 Study

Annals of Medicine

Volumn 45, Issue 2, 2013, Pages 141-148

  Oksala, Niku ^a   Seppälä, Ilkka ^a   Hernesniemi, Jussi ^a   Lyytikäinen, Leo Pekka ^a   Kähönen, Mika ^a   Mäkelä, Kari Matti ^a   Reunanen, Antti ^b   Jula, Antti ^b   Ala Korpela, Mika ^c   Lehtimäki, Terho ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c UNIVERSITY OF OULU   (Finland)

Author keywords

Apolipoproteins; cardiovascular; computational methods; events; extended; Friedewald; mortality; neural networks

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ANALYSIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; EXTENDED FRIEDEWALD APPROACH; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COMPUTER SIMULATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TRIGLYCERIDES;

EID: 84873336570     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2012.679962     Document Type: Article

References (43)

1. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
2. Warnick GR, Myers GL, Cooper GR, Rifai N. Impact of the third cholesterol report from the adult treatment panel of the national cholesterol education program on the clinical laboratory. Clin Chem. 2002;48:11-17.
3. Mora S, Rifai N, Buring JE, Ridker PM. Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women. Clin Chem. 2009;55:888-94.
4. Hodis HN, Mack WJ, Dunn M, Liu C, Liu C, Selzer RH, et al. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation. 1997;95:2022-6.
5. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation. 1993;88:2762-70.
6. Majeed F, Miller M. Low high-density lipoprotein cholesterol: an important consideration in coronary heart disease risk assessment. Curr Opin Endocrinol Diabetes Obes. 2008;15:175-81.
7. Bruckert E, Hansel B. HDL-c is a powerful lipid predictor of cardiovascular diseases. Int J Clin Pract. 2007;61:1905-13.
8. Morgan J, Carey C, LincoffA, Capuzzi D. High-density lipoprotein subfractions and risk of coronary artery disease. Curr Atheroscler Rep. 2004;6:359-65.
9. Lamarche B, Moorjani S, Lupien PJ, Cantin B, Bernard PM, Dagenais GR, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a fi ve-year follow-up of men in the Quebec cardiovascular study. Circulation. 1996;94:273-8.
10. Gotto AM Jr, Whitney E, Stein EA, Shapiro DR, Clearfi eld M, Weis S, et al. Relation between baseline and on-treatment lipid parameters and fi rst acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000;101:477-84.
11. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358:2026-33.
12. McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfi eld J, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008;372:224-33.
13. Mudd JO, Borlaug BA, Johnston PV, Kral BG, Rouf R, Blumenthal RS, et al. Beyond low-density lipoprotein cholesterol: defi ning the role of low-density lipoprotein heterogeneity in coronary artery disease. JAm Coll Cardiol. 2007;50:1735-41.
14. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation. 2005;112: 3375-83.
15. S t-Pierre AC, Cantin B, Dagenais GR, Mauriè g e P, Bernard PM, Despr és JP, et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol. 2005;25:553-9.
16. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. JLipid Res. 1995;36:211-28.
17. Brufau G, Groen AK, Kuipers F. Reverse cholesterol transport revisited: contribution of biliary versus intestinal cholesterol excretion. Arterioscler Thromb Vasc Biol. 2011;31:1726-33.
18. Tremblay AJ, Morrissette H, Gagne JM, Bergeron J, Gagne C, Couture P. Validation of the Friedewald formula for the determination of lowdensity lipoprotein cholesterol compared with beta-quantifi cation in a large population. Clin Biochem. 2004;37:785-90.
19. Niemi J, Makinen VP, Heikkonen J, Tenkanen L, Hiltunen Y, Hannuksela ML, et al. Estimation of VLDL, IDL, LDL, HDL(2), apoA-I, and apoB from the Friedewald inputs-apoB and IDL, but not LDL, are associated with mortality in type 1 diabetes. Ann Med. 2009;41:451-61.
20. Kattainen A, Salomaa V, Harkanen T, Jula A, Kaaja R, Kesän iemi YA, et al. Coronary heart disease: from a disease of middle-aged men in the late 1970s to a disease of elderly women in the 2000s. Eur Heart J. 2006;27:296-301.
21. Pajunen P, Koukkunen H, Ketonen M, Jerkkola T, Immonen-RäihäP, Kärj ä-Koskenkari P, et al. The validity of the Finnish Hospital Discharge Register and Causes of Death Register data on coronary heart disease. Eur J Cardiovasc Prev Rehabil. 2005;12:132-7.
22. Pencina MJ, D'A gostino RB Sr, Steyerberg EW. Extensions of net reclassifi cation improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30:11-21.
23. Pencina MJ, D'Agostino RB, Vasan RS. Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med. 2010;48:1703-11.
24. Kundu S, Aulchenko YS, van Duijn CM, Janssens AC. PredictABEL: an R package for the assessment of risk prediction models. Eur J Epidemiol. 2011;26:261-4.
25. Harrell, F. E. ImproveProb() routine in Hmisc package, R package version 3.9-0. Nashville, Tennessee Vanderbilt University Department of Biostatistics. URL: http://biostat.mc.vanderbilt.edu/s/Hmisc.
26. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profi le for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743-53.
27. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006;26: 847-70.
28. Teng B, Thompson GR, Sniderman AD, Forte TM, Krauss RM, Kwiterovich PO Jr. Composition and distribution of low density lipoprotein fractions in hyperapobetalipoproteinemia, normolipidemia, and familial hypercholesterolemia. Proc Natl Acad Sci USA. 1983;80: 6662-6.
29. Otvos J. Measurement of triglyceride-rich lipoproteins by nuclear magnetic resonance spectroscopy. Clin Cardiol. 1999;22(6 Suppl): II21-7.
30. Pradhan A. Obesity, metabolic syndrome, and type 2 diabetes: infl ammatory basis of glucose metabolic disorders. Nutr Rev. 2007;65(Pt 2): S152-6.
31. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration; Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, et al. Triglyceridemediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375:1634-9.
32. Talayero BG, Sacks FM. The role of triglycerides in atherosclerosis. Curr Cardiol Rep. 2011;13:544-52.
33. Natarajan P, Ray KK, Cannon CP. High-density lipoprotein and coronary heart disease: current and future therapies. JAm Coll Cardiol. 2010;55:1283-99.
34. Kontush A, Chapman MJ. Antiatherogenic small, dense HDL-guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med. 2006;3: 144-53.
35. Meisinger C, Loewel H, Mraz W, Koenig W. Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. Eur Heart J. 2005;26:271-8.
36. Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy-a review of the evidence. JIntern Med. 2006;259:493-519.
37. Juonala M, Viikari JS, Kahonen M, Solakivi T, Helenius H, Jula A, et al. Childhood levels of serum apolipoproteins B and A-I predict carotid intima-media thickness and brachial endothelial function in adulthood: the cardiovascular risk in young Finns study. JAm Coll Cardiol. 2008;52:293-9.
38. Sierra-Johnson J, Fisher RM, Romero-Corral A, Somers VK, Lopez-Jimenez F, Ohrvik J, et al. Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: fi ndings from a multi-ethnic US population. Eur Heart J. 2009;30:710-7.
39. Thompson A, Danesh J. Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. JIntern Med. 2006;259:481-92.
40. Luc G, Bard JM, Ferrieres J, Evans A, Amouyel P, Arveiler D, et al. Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Arterioscler Thromb Vasc Biol. 2002;22:1155-61.
41. Silva RA, Huang R, Morris J, Fang J, Gracheva EO, Ren G, et al. Structure of apolipoprotein A-I in spherical high density lipoproteins of different sizes. Proc Natl Acad Sci USA. 2008;105:12176-81.
42. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31:811-22.
43. Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult-2009 recommendations. Can J Cardiol. 2009;25:567-79.